Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
Francesco Bonella,1 Susanne Stowasser,2 Lutz Wollin3 1Interstitial and Rare Lung Disease Unit, Ruhrlandklinik, University Hospital, University of Duisburg-Essen, Essen, 2Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, 3Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der...
Saved in:
Main Authors: | Bonella F (Author), Stowasser S (Author), Wollin L (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2015-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Affinity of Nintedanib Towards New Candidate Target for Idiopathic Pulmonary Fibrosis
by: Hari Baskar Balasubramanian, et al.
Published: (2024) -
Efficacy and safety of combination therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
by: Jin-Young Huh, et al.
Published: (2023) -
Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib
by: Woodcock HV, et al.
Published: (2013) -
South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
by: Shaney L. Barratt, et al.
Published: (2018) -
Update on therapeutic management of idiopathic pulmonary fibrosis
by: Tzouvelekis A, et al.
Published: (2015)